vy-aadc01
Gene therapyexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2013 (NCT01973543)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DOPA decarboxylaseSupplementation
DDC supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vy-aadc01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03065192 | Phase 1 | May 11, 2017 | Voyager Therapeutics |
| NCT01973543 | Phase 1 | Oct 1, 2013 | Feinstein Institute for Medical Research, Oregon Health and Science University, University of California, San Francisco, Veristat, Inc., Voyager Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Voyager Therapeutics | For profit | 2 | 2 | 1 | 2013 |
| Feinstein Institute for Medical Research | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Veristat, Inc. | For profit | 1 | 0 | 1 | 2013 |
5 organizations
Page 1 / 1